Is URGN a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for UroGen Pharma (URGN) rests on The Zusduri launch curve: Zusduri went from roughly $29M in the first quarter of 2026 to ~$50.4M in the second and ~$68.0M in the third, and the underlying adoption metrics moved with it: 1,538 activated sites of care at September 30 (up from 1,444), 662 unique prescribers (up from 452), and 331 repeat prescribers, or about 50% of prescribers, up from 45% a quarter earlier. The bear case rests on the company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025. Analysts covering it publish targets from $54.00 to $75.00 against a $27.65 share price on November 20, 2026, so even the professionals disagree by 35% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
URGN key stats
At $27.65 on November 20, 2026, UroGen Pharma (URGN) has a market cap of $1.4B.
- Market cap
- $1.4B
- P/E (forward)
- 11.1
- Beta
- 1.64
Market cap, P/E and yield are measured at the $27.65 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with UroGen Pharma (URGN)?
The last two weeks for UroGen Pharma, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- URGN closed at $27.65 on November 20, 2026, up 5.6% over the past five trading days (from $26.18).
UroGen Pharma filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
UroGen Pharma (Nasdaq: URGN) develops and sells drugs that treat urothelial cancers without surgery. Its core technology is RTGel, a reverse-thermal hydrogel that is liquid when cold and turns to gel at body temperature, which lets a chemotherapy agent sit against tumor tissue in the bladder or upper urinary tract long enough to work. Two products built on it are approved. Jelmyto, cleared in 2020, treats low-grade upper tract urothelial cancer. Zusduri, cleared in June 2025, treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and is the first FDA-approved alternative to repeated transurethral resection surgery for that population. Behind them sit UGN-103 (a reformulated follow-on whose NDA the FDA accepted in October 2026, with a June 14, 2027 PDUFA target date), UGN-104 in upper tract disease, and UGN-501, an oncolytic virus that dosed its first Phase 1 patient in November 2026. The company has about 300 employees and is run by CEO Liz Barrett. The investment picture changed shape over the past year. Third-quarter 2026 revenue was ~$89.0M against ~$27.5M a year earlier, with Zusduri contributing ~$68.0M, up ~35% sequentially, and the company posted operating income of ~$8.3M, up from ~$0.1M in the June quarter, while keeping full-year operating expense guidance at ~$260M to $270M, toward the upper end. Gross margin ran about 91.6%, which is what makes the operating leverage credible if the ramp holds. Net loss narrowed to ~$1.5M ($0.03 per share), but analysts had expected a profit of about $0.11, and the company cut 2026 Jelmyto guidance to about $90M from ~$97M to $101M; the shares fell on the results. The balance sheet is the counterweight: ~$90.5M of cash and marketable securities against ~$196M of debt and a prepaid forward obligation owed to RTW on future product sales, leaving a shareholders' deficit of ~$125M. The stock nearly tripled off its October 2025 low to about $47 and a ~$2.3B market cap in August 2026, then gave back part of that move, closing near $31.68 on November 20, 2026 (a ~$1.55B market cap, up about 40% year to date and about 28% over one year). What is being priced is still Zusduri becoming a large franchise, not what it has already sold. In August 2026 UroGen also widened its pipeline beyond RTGel, agreeing to invest up to $7M ($4M of it invested in the third quarter) in IntraGel Therapeutics in exchange for a research license to IntraGel's biodegradable SRGel sustained-release platform, options on up to three oncology products built on it, and an option on TumoCure, an intratumoral cisplatin gel for advanced head and neck cancer, after a Phase 2 study.
The bull case: what would have to be true for $75.00
The most optimistic published target on URGN is $75.00, +171.2% from the $27.65 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. The Zusduri launch curve
Zusduri went from roughly $29M in the first quarter of 2026 to ~$50.4M in the second and ~$68.0M in the third, and the underlying adoption metrics moved with it: 1,538 activated sites of care at September 30 (up from 1,444), 662 unique prescribers (up from 452), and 331 repeat prescribers, or about 50% of prescribers, up from 45% a quarter earlier. Repeat use is the number that matters most, because it separates trial of a new product from a change in practice. Sequential growth slowed from ~73% to ~35%, which is the expected shape of a launch curve but is also what the market reacted to. Management has not guided full-year Zusduri revenue. For the December quarter, analysts expect total revenue of about $107M and EPS of about $0.39, which would be the first quarterly net profit.
2. Operating leverage arriving faster than expected
The September quarter produced operating income of ~$8.3M on ~91.6% gross margin, against an operating loss of ~$27.4M a year earlier and ~$0.1M of operating income in June. Net loss narrowed to ~$1.5M ($0.03 per share) from ~$33.3M, with the remaining gap driven by ~$4.8M of interest on the Pharmakon term loan and ~$4.5M of non-cash financing expense on the RTW obligation. The result still missed a ~$0.11 EPS estimate because the company is spending the incremental gross profit: R&D rose to ~$26.0M and SG&A to ~$47.2M, and 2026 operating expense guidance of ~$260M to $270M is now expected toward the upper end.
3. Lifecycle extension and patent runway
UGN-103 is a reformulated version of the same mitomycin plus RTGel combination with simpler manufacturing and reconstitution, and showed 94.5% six-month duration of response in the Phase 3 UTOPIA trial against 91.9% for Zusduri in ENVISION. The FDA accepted the NDA in October 2026 with a PDUFA target action date of June 14, 2027, and UroGen plans to submit 12-month duration data during review and to start a roughly 300-patient Phase 3 trial, LONGVIEW-HR, in high-risk disease in the fourth quarter of 2026. A US method-of-treatment patent covering recurrent low-grade intermediate-risk NMIBC has now issued and is expected to run into July 2044, covering both Zusduri and, if approved, UGN-103, which matters because Zusduri's regulatory exclusivity alone expires in June 2028.
4. Jelmyto as the mature base with a dated end
Jelmyto generated ~$21.0M in the September quarter, down from ~$25.7M a year earlier and including a one-time ~$1.5M unfavorable gross-to-net adjustment tied to a CMS discarded-drug true-up. UroGen cut full-year 2026 Jelmyto guidance to about $90M from ~$97M to $101M, citing that adjustment and competitive trial enrollment affecting patient starts, which puts the product slightly below the ~$94M booked in 2025. UroGen settled Teva's ANDA challenge in June 2026 by licensing a generic entry date of September 15, 2030. That converts an open-ended legal risk into a known cliff, which is useful for modelling but does not make the decline go away.
The bear case: what would have to be true for $54.00
The most pessimistic published target is $54.00, +95.3% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks UroGen Pharma is worth if the risks below bite instead of the drivers above.
The company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025. Its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year, and at-the-market equity capacity makes dilution an available lever. Concentration risk is severe: two products, one delivery technology, and one therapeutic area, with Zusduri now about three quarters of revenue after roughly a year on the market. A launch curve this steep can flatten quickly if reimbursement, site onboarding, or repeat prescribing stalls, and sequential growth already slowed from ~73% to ~35% in the third quarter. Competition is arriving from several directions at once, including newly approved intravesical therapies in adjacent bladder cancer settings, competing clinical trials that management says are pulling Jelmyto patient starts, and cheap compounded chemotherapy regimens that urology practices already use. Jelmyto faces generic entry in September 2030 and Zusduri loses regulatory exclusivity in June 2028, so the patent running to 2044 has to hold up to be worth what the market is assigning it. The share price itself has become a risk signal: the stock fell about 32% over the three months to November 20, 2026, from a 52-week high of about $50.81, and dropped after the third-quarter EPS miss, while options implied volatility has been rising.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding URGN already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on URGN
7 analysts cover URGN, with an average target of $60.71 (+119.6% against $27.65) and a split of 7 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the URGN forecast and price target page.
How is URGN valued?
Market cap, P/E and dividend yield at today's price are in the URGN key stats above. The business figures below come from UroGen Pharma's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$250M (latest quarter up ~224% year over year)
- Revenue (Q3 2026): ~$89.0M (Zusduri ~$68.0M, Jelmyto ~$21.0M)
- Net loss (Q3 2026 / TTM): ~$1.5M (~$0.03 per share, vs ~$0.11 profit expected) / ~$66M
- Gross margin: ~91%
- Cash & total debt: ~$91M and ~$196M (plus RTW prepaid forward obligation)
As of November 2026: There is no meaningful trailing P/E because UroGen is still loss-making over the last twelve months, roughly ~$66M of net loss, so the shares are framed on sales multiples and on how quickly the Zusduri ramp closes the gap. About ~$1.55B of market value against ~$250M of trailing revenue is roughly 6x sales, and analysts' 2027 estimates (revenue near $535M, EPS near $2.50) put the forward P/E around 13x, which is what the stock is being priced on; the mean analyst target of ~$60.71 from seven analysts sits well above the price. Debt and the RTW obligation still matter here, unlike for a cash-rich clinical-stage biotech, and the next data point is fourth-quarter results in early 2027.
How do you decide if URGN is a buy?
Whether URGN is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold URGN indirectly through an index or sector ETF before adding more.
What would change your mind on URGN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: The Zusduri launch curve stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: the company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025 fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the URGN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about URGN against your real portfolio and see your actual exposure before deciding.
Your questions about UroGen Pharma
Ask Walnut's AI anything about URGN and see how it fits what you own.
FAQ
Is URGN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on The Zusduri launch curve, with revenue (ttm) at ~$250M (latest quarter up ~224% year over year). The bear case rests on the company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025. Analysts covering it are spread from $54.00 to $75.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell URGN?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $54.00, +95.3% from the $27.65 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for URGN?
+
The Zusduri launch curve. Zusduri went from roughly $29M in the first quarter of 2026 to ~$50.4M in the second and ~$68.0M in the third, and the underlying adoption metrics moved with it: 1,538 activated sites of care at September 30 (up from 1,444), 662 unique prescribers (up from 452), and 331 repeat prescribers, or about 50% of prescribers, up from 45% a quarter earlier. The most optimistic analyst target on URGN is $75.00, +171.2% from the $27.65 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for URGN?
+
The company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025. Its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year, and at-the-market equity capacity makes dilution an available lever. Concentration risk is severe: two products, one delivery technology, and one therapeutic area, with Zusduri now about three quarters of revenue after roughly a year on the market. A launch curve this steep can flatten quickly if reimbursement, site onboarding, or repeat prescribing stalls, and sequential growth already slowed from ~73% to ~35% in the third quarter. Competition is arriving from several directions at once, including newly approved intravesical therapies in adjacent bladder cancer settings, competing clinical trials that management says are pulling Jelmyto patient starts, and cheap compounded chemotherapy regimens that urology practices already use. Jelmyto faces generic entry in September 2030 and Zusduri loses regulatory exclusivity in June 2028, so the patent running to 2044 has to hold up to be worth what the market is assigning it. The share price itself has become a risk signal: the stock fell about 32% over the three months to November 20, 2026, from a 52-week high of about $50.81, and dropped after the third-quarter EPS miss, while options implied volatility has been rising. The most pessimistic published target is $54.00, +95.3% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does UroGen Pharma do?
+
UroGen Pharma develops and sells drugs that treat urothelial cancers without surgery, using a reverse-thermal hydrogel that holds chemotherapy against tumor tissue.
What would have to change for URGN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The Zusduri launch curve) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does UroGen Pharma actually sell?
+
Two approved drugs. Jelmyto treats low-grade upper tract urothelial cancer and has been on the market since 2020. Zusduri, approved in June 2025, treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both use UroGen's RTGel hydrogel, which turns from liquid to gel at body temperature so the chemotherapy stays in contact with tumor tissue instead of washing out.
Is URGN profitable?
+
Not yet on a net basis. The September 2026 quarter produced operating income of about $8.3M, up from ~$0.1M in June, but interest on the term loan and non-cash financing expense on the RTW obligation still left a net loss of ~$1.5M ($0.03 per share), short of the ~$0.11 profit analysts expected. Trailing twelve-month net loss is roughly ~$66M, down sharply from the prior year as Zusduri revenue scaled. Analysts expect about $0.39 of EPS in the fourth quarter of 2026, which would be the first positive quarterly EPS.
Why did revenue more than triple year over year?
+
Zusduri. It contributed ~$68.0M in the third quarter of 2026, up ~35% from the second quarter, against only a few months of sales in the year-ago period, since FDA approval came in June 2025. Jelmyto was ~$21.0M and lower than a year earlier. Any trailing-twelve-month figure for UroGen (about $250M) understates the current run rate because it still contains early-launch quarters.
Walnut is informational, not investment advice, and gives no verdict on URGN. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.